Some intermediate and late stage lung cancer patients can live for five years after surgery, and the proportion of intermediate stage patients who can live for five years is higher than that of late stage patients. After radical surgery, the five-year survival rate of intermediate stage lung cancer patients is about 30%. Therefore, in order to improve the cure rate and survival rate of patients, adjuvant chemotherapy or radiotherapy is given after surgery, and some of them are given targeted therapy, etc. If patients can receive immunotherapy, it may prolong their survival for a certain period of time. If the patient can receive immunotherapy, it may prolong the survival for a certain period of time. If the pathological type is adenocarcinoma and there is a mutation in the gene test, the survival period may be longer with immunotherapy. Most patients with advanced lung cancer cannot undergo radical surgery or palliative tumor reduction surgery, and the 5-year survival rate is relatively low. However, in recent years, targeted drugs and immunotherapy have been effective for patients with advanced lung cancer, and the survival period of patients has been gradually extended. It is suggested that lung cancer patients should go to regular hospitals in time and listen to the advice of professional doctors.